Compare GLPG & BATRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLPG | BATRK |
|---|---|---|
| Founded | 1999 | 1991 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | N/A | N/A |
| Metric | GLPG | BATRK |
|---|---|---|
| Price | $34.53 | $43.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $31.33 | ★ $58.00 |
| AVG Volume (30 Days) | 98.5K | ★ 348.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.76 | $12.40 |
| Revenue Next Year | $0.49 | $6.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.59 | $35.46 |
| 52 Week High | $37.78 | $47.18 |
| Indicator | GLPG | BATRK |
|---|---|---|
| Relative Strength Index (RSI) | 59.21 | 76.63 |
| Support Level | $33.39 | $38.79 |
| Resistance Level | $34.22 | $40.11 |
| Average True Range (ATR) | 0.62 | 0.94 |
| MACD | -0.04 | 0.41 |
| Stochastic Oscillator | 79.83 | 87.25 |
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.